Intended Audience

This complimentary CME educational activity is designed for all cardiology-focused physicians, nurses, NPs, academicians, pharmacists, researchers, investigators, and program directors managing, referring, and/or consulting on patients with atrial fibrillation, with a focus on stroke prevention. We welcome neurology-focused clinicians with a medical and educational needs in the fields of general cardiology, and other providers that are part of the multidisciplinary team caring for patients with these and related conditions, including:

• Cardiologists
• Preventive cardiologists
• Cardiovascular electrophysiologists
• Neurovascular specialists
• Neurologists
• Vascular biologists
• Anticoagulation experts
• Heart failure specialists
• Coronary care unit (CCU) specialists and directors
• Clinical pharmacists and pharmacologists
• Pharmacy directors cardiovascular medicine)
• Cardiovascular nurses

Program Medium

Internet-based program

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period August 10, 2012 through August 10, 2014 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 146 segments totaling 5 hours and 37 minutes to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate

Estimated Time to Complete Educational Activity

6.0 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in stroke prevention in the setting of atrial fibrillation.

Release Date

August 10, 2012

Expiration Date

August 10, 2014

Registration

Participation in this iQ&A interactive Medical Intelligence Zone for Thrombosis Risk Reduction is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from the Bristol-Myers Squibb/Pfizer Partnership



Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School Office of Continuing Medical Education (UMMS-OCME) and CMEducation Resources, LLC. The UMMS-OCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credits(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Samuel Z. Goldhaber, MD
Program Chairman and Moderator
Professor of Medicine
Harvard Medical School
Director, VTE Research Group
Cardiovascular Division
Brigham and Women's Hospital
President, North American Thrombosis Forum (NATF)
Boston, Massachusetts

Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eisai, and sanofi-aventis.
Research support: Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eisai, Johnson & Johnson Pharmaceutical Research & Development and sanofi-aventis

John Alexander, MD
Associate Professor of Medicine
Co-Director, CV Research
Duke Clinical Research Institute
Durham, NC

Research Support: Bristol Myers Squibb, Medtronic Japan, NIH, Portola Pharma, Regado Biosciences, Medicure, Millennium Pharmaceuticals, Momenta Pharma, Schering Plough
Consulting / Honorarium: Adolor, Astra Zeneca, Daiichi Sankyo, Medicure, NIH, Novartis, Pfizer

Dan Atar, MD, PhD
Professor
Department of Cardiology
Oslo University Hospital Ullevaal
Oslo, Norway

Speaker and Consultant: BMS/Pfizer, Bayer, Boehringer-Ingelheim, Merck, sanofi-aventis

Richard C. Becker, MD
Professor of Medicine
School of Medicine
Duke University
Director, Duke Cardiovascular Thrombosis Center
Duke Clinical Research Institute
Durham, North Carolina

Grant/Research Support: Johnson & Johnson, Bristol-Myers Squibb, Bayer, Merck, Regado Biosciences

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular
Program, Brigham and Women’s Hospital and the
VA Boston Healthcare System
Senior Investigator, TIMI Group
Harvard Medical School
Boston, Massachusetts

Consultant: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson & Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, Takeda, The Medicines Company, Vertex.
Principal Investigator for several potentially related studies. His institution has received funding from Bristol Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, The Medicines Company

Harry R. Büller, MD, PhD
Professor of Medicine
Dept. of Vascular Medicine
Academic Medical Center
Amsterdam, The Netherlands

Nothing to disclose

Christopher Cannon, MD
Senior Investigator, TIMI Study Group, Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Research Grants/Support: Accumetrics, AstraZeneca, GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda; Advisory Board: Alnylam, Bristol-Myers Squibb/Sanofi, Novartis; Honorarium for Development of Independent Educational Symposia: AstraZeneca, Pfizer; Clinical Advisor/Equity: Automedics Medical Systems.

Michael D. Ezekowitz, MD, PhD
Professor and Vice President
Lankenau Institute for Medical Research
Vice President, Clinical Research
Main Line Hospitals
Wynnewood, Pennsylvania

Advisor or Consultant: Boehringer Ingelheim Pharmaceuticals, Inc.; ARYx Therapeutic; Pfizer Inc.; sanofi-aventis; Bristol-Myers Squibb Company; Portola Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Medtronic, Inc.
Grants/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc.; ARYx Therapeutic; Portola Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.

Greg Flaker MD
Professor of Medicine
Wes and Simon Chair of Cardiovascular Research
University of Missouri School of Medicine
Columbia, MO

Consultant: Boehringer-Ingelheim
Grant/Research Support: Boehringer-Ingelheim

Keith A. A. Fox, MB, ChB
Professor of Cardiology
Cardiovascular Research
Division of Medical & Radiological Science
University of Edinburgh
Edinburgh, United Kingdom

Advisor or consultant: Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eli Lilly and Company; sanofi-aventis
Speaker or a member of a speakers bureau: Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eli Lilly and Company; sanofi-aventis
Research Support: Bayer HealthCare Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.

Bernard Gersh, MB, ChB, FRCP, DPhil
Professor of Medicine
Division of Cardiovascular Diseases
Mayo Clinic and Foundation
Rochester, Minnesota

Advisor or consultant: Ortho-McNeil-Janssen Pharmaceuticals, Inc., Amorcyte, Inc., Abbott Laboratories, Merck & Co., GE Healthcare, St. Jude Medical, Medispec LTD, Boston Scientific

Samuel Z. Goldhaber, MD
Professor of Medicine
Division of Cardiovascular Medicine
Brigham and Women’s Hospital
Harvard Medical School
Director, North American Thrombosis Forum
Boston, MA

Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eisai, and sanofi-aventis.
Research support: Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eisai, Johnson & Johnson Pharmaceutical Research & Development and sanofi-aventis

Christopher B. Granger, MD
Professor of Medicine
Director
Cardiac Care Unit; Co-Director
Cardiovascular Clinical Trials
Duke University Medical Center
Durham, North Carolina

Advisor or Consultant: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; sanofi-aventis; The Medicines Company
Grants/Research Support: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Eli Lilly and Company; Medtronic, Inc.; Merck & Co., Inc.; sanofi-aventis; The Medicines Company

Jonathan L. Halperin, MD
Mount Sinai School of Medicine
Director, Clinical Cardiology Services
The Zena and Michael A. Wiener Cardiovascular Institute
The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health
Mount Sinai Medical Center
New York, New York

Consultant: Astellas Pharma, U.S., Bayer HealthCare, Biotronik, Inc, Boehringer-Ingelheim, Daiichi-Sankyo Pharma, Johnson & Johnson, Portola Pharmaceuticals, Sanofi-Aventis

Stefan H. Hohnloser, MD
Director, Department of Clinical Electrophysiology
J. W. Goethe University
Frankfurt, Germany

Consultant: sanofi-aventis, Boehringer Ingelheim, St. Jude Medical, Cardiome Pharma Corp.,  ARYx Therapeutics, Bristol-Myers Squibb
Speaker/Speaker’s Bureau: sanofi-aventis, Boehringer Ingelheim, St. Jude Medical, Cardiome Pharma Corp., ARYx Therapeutics,  Bristol-Myers Squibb
Grant/Research Support: sanofi-aventis, St. Jude Medical

Elaine M. Hylek, MD, MPH
Associate Professor of Medicine
Department of Medicine
Boston University Medical Center
Boston, Massachusetts

Advisory Boards: Bristol-Myers Squibb, sanofi-aventis, Boehringer-Ingelheim

Ajay Kakkar, MBBS, PhD, FRCS
Head of the Centre for Surgical Sciences
Barts and the London
Queen Mary's School of Medicine and Dentistry
Thrombosis Research Institute
London, UK

Consultant: Pfizer, Bristol-Myers Squibb, sanofi-aventis, Boehringer-Ingelnheim, Bayer, GlaxoSmithKline, Eisai, Aryx
Grant/Research Support: Pfizer, Bristol-Myers, Squibb, sanofi0aventis, Boehringer-Ingelnheim, Bayer, GlaxoSmithKline, Eisai, Aryx

Peter R. Kowey, MD
W.W. Smith Chair and Chief of Cardiology
Main Line Health Professor of Medicine and Clinical Pharmacology
Jefferson Medical College
Philadelphia, PA

Consultant: Daiichi-Sankyo, Boehringer-Ingelheim, Johnson & Johnson, Bristol-Myers Squibb, Merck, Portola

Gregory Y.H. Lip, MD, FRCP, FACC, FESC
Consultant Cardiologist and Professor of Cardiovascular Medicine
Director, Haemostasis Thrombosis & Vascular Biology Unit
University of Birmingham Centre for Cardiovascular Sciences
City Hospital
Birmingham, England

Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Bayer HealthCare Pharmaceuticals; Merck & Co., Inc.; Astellas Pharma, Inc.; Portola Pharmaceuticals, Inc.; BIOTRONIK, Inc.; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Pfizer Inc
Speaker or a member of a speakers bureau: Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company; Pfizer Inc.

Renato D. Lopes, MD, PhD
Adjunct Professor of Medicine
Duke University Medical Center
Durham, NC
Faculty
Federal University of São Paulo
Executive Director
Brazilian Clinical Research Institute
São Paulo, Brazil

Advisor or consultant: Boehringer Ingelheim Pharmaceuticals, Inc. Received grants for clinical research from: Bristol-Myers Squibb Company

Kenneth W. Mahaffey, MD
Associate Professor of Medicine
Duke University Health System
Faculty, Director, Clinical Events Classification (CEC) Group
Duke Clinical Research Institute
Durham, NC

Grant/Research Support: Abbott Laboratories; Amgen Inc.; Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; CardioKinetix Inc.; Cierra, Inc.; Cordis Corporation; Edwards Lifesciences; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Guidant Corporation; Innocoll, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; KCI; Luitpold Pharmaceuticals; Medtronic, Inc.; Merck & Co., Inc.; Momenta Pharmaceuticals, Inc.; Novartis Pharmaceuticals; Portola Pharmaceuticals, Inc.; POZEN Inc.; Regado Biosciences; sanofi-aventis; Schering-Plough; The Medicines Company
Consultant: Adolor Corporation; Alexion Pharmaceuticals, Inc.; Amgen Inc.; Argolyn Bioscience, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; Duke University School of Medicine; Eli Lilly and Company; Elsevier B.V.; Forest Laboratories, Inc.; Genentech, Inc.; GlaxoSmithKline; Guidant Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck & Co., Inc.; Novartis; Pfizer Inc.; Procter & Gamble; sanofi-aventis; Schering-Plough; Scios Inc

Gerald V. Naccarelli, MD
Bernard Trabin Chair in Cardiology
Professor of Medicine
Chief, Division of Cardiology
Penn State Heart and Vascular Institute
Hershey, PA

Advisor or consultant: Otsuka Pharmaceutical Co. Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Pfizer Inc.; AstraZeneca Pharmaceuticals LP; Paracor; Transoma; Medtronic, Inc.; sanofi-aventis; CV Therapeutics; Cardiome Pharma Corp.; Novartis Pharmaceuticals Corporation; Wyeth Pharmaceuticals Inc.; Xention; Astellas Pharma, Inc.; GlaxoSmithKline; Biocritique.
Research Support: GlaxoSmithKline; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Medtronic, Inc.; sanofi-aventis.

Alexander G. G. Turpie, MD, FRCP, FACP, FACC, FRCPC
Professor of Medicine, Emeritus
Department of Medicine
Hamilton Health Sciences-General Hospital
Hamilton, Ontario
Canada

Consultant: Bayer, Johnson & Johnson, Pfizer, Astellas
Speaker’s Bureau: GlaxoSmithKline, Bayer Canada

Freek Verheugt, MD, PhD
Professor of Cardiology
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands

Grant/Research Support: Bayer AG; Consultant/Honoraria: AstraZeneca Pharmaceuticals LP, Bayer AG, Bristol-Myers Squibb/Pfizer Inc, Novartis Pharmaceuticals Corporation

Lars Wallentin, MD, PhD
Professor of Cardiology
Director, Uppsala Clinical Research Center
University Hospital
Uppsala, Sweden

Grant/Research Support: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Schering-Plough Corporation

Jeffrey I. Weitz, MD FRCP, FACP
Professor of Medicine and Biochemistry
McMaster University
Canada Research Chair in Thrombosis
Heart and Stroke Foundation
J.F. Mustard Chair in Cardiovascular Research

Honoraria: Bristol-Myers Squibb, Daiichi-Sankyo, Takeda
Consultant: Boehringer-Ingelheim, sanofi-aventis, The Medicines Company, Bayer, Bristol-Myers Squibb, Eisai, Daiichi-Sankyo, Takeda

Salim Yusuf, MD
Professor of Medicine
Director
Population Health Research Institute
McMaster University
Hamilton, Ontario

Research support: sanofi-aventis, Bristol-Myers Squibb Company.
Consultant: sanofi-aventis, Bristol-Myers Squibb Company.
Speaker or speaker’s bureau: sanofi-aventis, Bristol-Myers Squibb Company

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.
Program Reviewer Denise Leary has nothing to disclose


Educational Objectives

Upon completion of this activity, participants will:

• Have a better, more scientific and clinically relevant understanding of advances in oral anticoagulation based on new mechanisms involving inhibition of the coagulation cascade; and the possible implications of these advances for prophylaxis of arterial thromboembolism in the setting of atrial fibrillation
• Be able to apply national guidelines—including those issues by the ACC, AHA, , ASA, ACCP, and others—so that they can overcome practice gaps and improve thrombosis management and clinical outcomes in patients with AF and other risk factors for stroke.
• Have a better, more scientific and evidence-based understanding of how systemic anticoagulation can prevent stroke in the setting of AF, and be better skilled at using multiple approaches, including established, evidence-based, guideline-sanctioned treatments with VKAs and, when available, emerging therapies affecting other targets in the coagulation cascade.
• Better understand the epidemiology, scope of problem, risk stratification (CHADS2), landmark trials, national guidelines, and the multidimensional therapeutic landscape of antithrombotic strategies shown to be useful for stroke risk reduction in AF.
• Have a better, more scientific understanding of the mechanisms involved in thromboembolic prevention in heart disease and the rationale for identifying agents with predictable anticoagulation, in the absence of clinical monitoring.
• Have a better, more scientific understanding about novel approaches for residual risk reduction and secondary prevention of adverse thromboembolic events (stroke) in the setting of atrial fibrillation and be able to make more evidence-based clinical decisions that account for both thrombosis mitigation and bleeding risks when selecting anticoagulation strategies.
• Be able to apply the landmark clinical trials focusing on thromboembolic risk prevention in patients with atrial fibrillation to the front lines of clinical practice in order to reduce stroke risk.

Disclaimer

Copyright © 2012 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © CMEducation Resources, LLC and Pharmatecture, LLC